News
| Type | Title | Date |
|---|---|---|
| Press Release | Ablative Solutions, Inc. Announces TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation | April 11, 2024 |
| Press Release | Ablative Solutions, Inc. Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine SystemTM Kit for Patients with Uncontrolled Hypertension | December 19, 2023 |
| Press Release | Ablative Solutions, Inc. Announces Enrollment Completion of TARGET BP I Study for Patients with Uncontrolled Hypertension | April 12, 2023 |
| Press Release | Ablative Solutions, Inc. Announces Completion of the Fourth Tranche of its Series D Preferred Financing Round for Unique Therapeutic Approach to Treating Uncontrolled Hypertension | June 13, 2022 |
| Press Release | Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions | February 20, 2020 |
| Press Release | Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension | September 3, 2019 |
| Press Release | Ablative Solutions Announces Enrollment and Randomization of First Patient in Global Clinical Trial Evaluating Company’s Novel Therapy for Uncontrolled Hypertension | July 23, 2019 |
| Press Release | Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer | July 11, 2019 |
| Press Release | Ablative Solutions Announces Results from Treatment of Patients with Hypertension in the European Peregrine Post-Market Study | March 7, 2019 |
| Press Release | Ablative Solutions, Inc. Announces $77 Million Financing for Unique Therapeutic Approach to Treating Uncontrolled Hypertension | January 3, 2019 |
Events
| Type | Title | Location | Start Date | End Date |
|---|